<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38321333</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.</ArticleTitle><Pagination><StartPage>1335</StartPage><EndPage>1342</EndPage><MedlinePgn>1335-1342</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-024-07377-z</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Fatigue is a prominent symptom in post-COVID condition (PCC) sequelae, termed "long COVID." Herein, we aim to ascertain the effect of fatigue on psychosocial function in persons living with PCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This post hoc analysis evaluated the effects of vortioxetine on measures of fatigue as assessed by the Fatigue Severity Scale (FSS) in psychosocial function as measured by the Sheehan Disability Scale (SDS) in persons with PCC. We also evaluated the change in FSS on psychosocial functioning as measured by the Sheehan Disability Scale (SDS). This post hoc analysis obtained data from a recently published placebo-controlled study evaluating vortioxetine's effect on objective cognitive functions in persons living with PCC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred forty-four participants meeting World Health Organization (WHO) criteria for PCC were included in this analysis. At the end of 8&#xa0;weeks of vortioxetine treatment, significant improvement of all domains was observed for psychosocial functioning. There was a significant between-group difference at treatment endpoint in the family, social, and work SDS subcategories (p&#x2009;&lt;&#x2009;0.001). There was a statistically significant interaction effect between the treatment condition time point and FSS effect on the SDS social&#xa0;(&#x3c7;<sup>2</sup> = 10.640, p = 0.014) and work (&#x3c7;<sup>2</sup> = 9.342, p = 0.025)&#xa0;categories but a statistically insignificant effect on the family categories ((&#x3c7;<sup>2</sup> = 5.201, p = 0.158)).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This post hoc analysis suggests that vortioxetine treatment significantly improves psychosocial function in persons with PCC. Our results also indicate that the improvement in psychosocial function was significantly mediated by improvement in measures of fatigue. Our results provide empirical support for recommendations to identify therapeutics for fatigue in persons living with PCC with a broader aim to improve psychosocial function in this common and severely impaired population.</AbstractText><CopyrightInformation>&#xa9; 2024. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Badulescu</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0001-6589-2906</Identifier><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Gia Han</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Angela T H</ForeName><Initials>ATH</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ziji</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teopiz</LastName><ForeName>Kayla M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniapillai</LastName><ForeName>Mehala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenblat</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada. roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada. roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3O2K1S3WQV</RegistryNumber><NameOfSubstance UI="D000078784">Vortioxetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078784" MajorTopicYN="N">Vortioxetine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000083623" MajorTopicYN="N">Psychosocial Functioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PCC</Keyword><Keyword MajorTopicYN="N">Patient-reported outcomes</Keyword><Keyword MajorTopicYN="N">Post-COVID condition (PCC)</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID (PASC)</Keyword><Keyword MajorTopicYN="N">Psychosocial functioning</Keyword><Keyword MajorTopicYN="N">Sheehan Disability Scale (SDS)</Keyword><Keyword MajorTopicYN="N">Vortioxetine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38321333</ArticleId><ArticleId IdType="doi">10.1007/s10072-024-07377-z</ArticleId><ArticleId IdType="pii">10.1007/s10072-024-07377-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, Assaf GS, McCorkell L et al (2021) Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38:101019. https://doi.org/10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId><ArticleId IdType="pmc">8280690</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker S, Goodfellow H, Pookarnjanamorakot P et al (2023) Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ Open 13(6):e069217. https://doi.org/10.1136/bmjopen-2022-069217</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069217</ArticleId><ArticleId IdType="pubmed">37286327</ArticleId><ArticleId IdType="pmc">10335413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K et al (2023) Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front Immunol 14:1129459. https://doi.org/10.3389/fimmu.2023.1129459</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1129459</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId><ArticleId IdType="pmc">10034329</ArticleId></ArticleIdList></Reference><Reference><Citation>Murga I, Aranburu L, Gargiulo PA, G&#xf3;mez Esteban JC, Lafuente JV (2021) Clinical heterogeneity in ME/CFS. A way to understand long-COVID19 fatigue. Front Psychiatry 12. https://www.frontiersin.org/articles/10.3389/fpsyt.2021.735784 . Accessed June 19, 2023</Citation></Reference><Reference><Citation>Rudroff T, Fietsam AC, Deters JR, Bryant AD, Kamholz J (2020) Post-COVID-19 fatigue: potential contributing factors. Brain Sci 10(12):1012. https://doi.org/10.3390/brainsci10121012</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10121012</ArticleId><ArticleId IdType="pubmed">33352638</ArticleId><ArticleId IdType="pmc">7766297</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AK, Kingstone T, Briggs TA et al (2021) &#x201c;Reluctant pioneer&#x201d;: a qualitative study of doctors&#x2019; experiences as patients with long COVID. Health Expect Int J Public Particip Health Care Health Policy 24(3):833&#x2013;842. https://doi.org/10.1111/hex.13223</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hex.13223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C, Freitag H, Meyer-Arndt L, et al. Chronic COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) following the first pandemic wave in Germany&#x2013;a first analysis of a prospective observational study. Published online February 8, 2021:2021.02.06.21249256. https://doi.org/10.1101/2021.02.06.21249256</Citation></Reference><Reference><Citation>Twomey R, DeMars J, Franklin K, Culos-Reed SN, Weatherald J, Wrightson JG (2022) Chronic fatigue and postexertional malaise in people living with long COVID: an observational study. Phys Ther 102(4):pzac005. https://doi.org/10.1093/ptj/pzac005</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/pzac005</ArticleId><ArticleId IdType="pubmed">35079817</ArticleId></ArticleIdList></Reference><Reference><Citation>Vink M, Vink-Niese A (2020) Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? Lessons from the Qure study for Q-fever fatigue syndrome. Healthc Basel Switz 8(4):552. https://doi.org/10.3390/healthcare8040552</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare8040552</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino A, English CD, Rey JA (2015) Vortioxetine (Brintellix): a new serotonergic antidepressant. Pharm Ther 40(1):36&#x2013;40</Citation></Reference><Reference><Citation>Santos Garc&#xed;a D, Alonso Losada MG, Cimas Hernando I et al (2022) Vortioxetine improves depressive symptoms and cognition in Parkinson&#x2019;s disease patients with major depression: an open-label prospective study. Brain Sci 12(11):1466. https://doi.org/10.3390/brainsci12111466</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12111466</ArticleId><ArticleId IdType="pubmed">36358393</ArticleId><ArticleId IdType="pmc">9688230</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS, Phan L, Kwan ATH, et al. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain. Published online November 4, 2023:awad377. https://doi.org/10.1093/brain/awad377</Citation></Reference><Reference><Citation>Cao B, Park C, Rosenblat JD et al (2019) Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: an open-label clinical trial. J Psychopharmacol Oxf Engl 33(11):1388&#x2013;1394. https://doi.org/10.1177/0339881119874485</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0339881119874485</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C, Ferini-Strambi L, Izzi F et al (2019) Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol 85(1):240&#x2013;244. https://doi.org/10.1111/bcp.13772</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13772</ArticleId><ArticleId IdType="pubmed">30328132</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh E, Clark DM (2018) Understanding social anxiety disorder in adolescents and improving treatment outcomes: applying the cognitive model of Clark and Wells (1995). Clin Child Fam Psychol Rev 21(3):388&#x2013;414. https://doi.org/10.1007/s10567-018-0258-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10567-018-0258-5</ArticleId><ArticleId IdType="pubmed">29654442</ArticleId><ArticleId IdType="pmc">6447508</ArticleId></ArticleIdList></Reference><Reference><Citation>Navaneetham P, Kanth B (2022) Effects of personal relationships on physical and mental health among young adults- a scoping review. Open Psychol J 15(1). https://doi.org/10.2174/18743501-v15-e2208180</Citation></Reference><Reference><Citation>Wu B (2020) Social isolation and loneliness among older adults in the context of COVID-19: a global challenge. Glob Health Res Policy 5(1):27. https://doi.org/10.1186/s41256-020-00154-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41256-020-00154-3</ArticleId><ArticleId IdType="pubmed">32514427</ArticleId><ArticleId IdType="pmc">7272234</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson D, Ian Noy Y, H&#xe4;rm&#xe4; M, &#xc5;kerstedt T, Belenky G (2011) Modelling fatigue and the use of fatigue models in work settings. Accid Anal Prev 43(2):549&#x2013;564. https://doi.org/10.1016/j.aap.2009.12.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aap.2009.12.030</ArticleId><ArticleId IdType="pubmed">21130216</ArticleId></ArticleIdList></Reference><Reference><Citation>Majer M, Welberg LAM, Capuron L, Miller AH, Pagnoni G, Reeves WC (2008) Neuropsychological performance in persons with chronic fatigue syndrome: results from a population-based study. Psychosom Med 70(7):829&#x2013;836. https://doi.org/10.1097/PSY.0b013e31817b9793</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PSY.0b013e31817b9793</ArticleId><ArticleId IdType="pubmed">18606722</ArticleId></ArticleIdList></Reference><Reference><Citation>Trecroci A, Boccolini G, Duca M, Formenti D, Alberti G (2020) Mental fatigue impairs physical activity, technical and decision-making performance during small-sided games. PLoS ONE 15(9):e0238461. https://doi.org/10.1371/journal.pone.0238461</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0238461</ArticleId><ArticleId IdType="pubmed">32903263</ArticleId><ArticleId IdType="pmc">7480836</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoun Sebaiti M, Hainselin M, Gounden Y et al (2022) Systematic review and meta-analysis of cognitive impairment in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Sci Rep 12(1):2157. https://doi.org/10.1038/s41598-021-04764-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-04764-w</ArticleId><ArticleId IdType="pubmed">35140252</ArticleId><ArticleId IdType="pmc">8828740</ArticleId></ArticleIdList></Reference><Reference><Citation>Shockey TM (2017) Short sleep duration by occupation group &#x2014; 29 states, 2013&#x2013;2014. MMWR Morb Mortal Wkly Rep 66. https://doi.org/10.15585/mmwr.mm6608a2</Citation></Reference><Reference><Citation>Caldwell JA, Caldwell JL, Thompson LA, Lieberman HR (2019) Fatigue and its management in the workplace. Neurosci Biobehav Rev 96:272&#x2013;289. https://doi.org/10.1016/j.neubiorev.2018.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2018.10.024</ArticleId><ArticleId IdType="pubmed">30391406</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R, Wey H, Foland K (2018) The relationship among change fatigue, resilience, and job satisfaction of hospital staff nurses. J Nurs Scholarsh 50(3):306&#x2013;313. https://doi.org/10.1111/jnu.12373</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnu.12373</ArticleId><ArticleId IdType="pubmed">29517141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J, Smith AP (2017) The impact of workload and fatigue on performance. In: Longo L, Leva MC (eds) Human mental workload: models and applications. Communications in computer and information science. Springer International Publishing, pp 90&#x2013;105. https://doi.org/10.1007/978-3-319-61061-0_6</Citation></Reference><Reference><Citation>Gil-Sanchez A, Canudes M, Valcheva P et al (2024) Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study. CNS Neurol Disord Drug Targets 23(3):395&#x2013;401. https://doi.org/10.2174/1871527323366230321093133</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527323366230321093133</ArticleId><ArticleId IdType="pubmed">36944623</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M (2023) Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry 28(2):564&#x2013;578. https://doi.org/10.1038/s41380-022-01836-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01836-9</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG (2018) Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol 175(1):113&#x2013;124. https://doi.org/10.1111/bph.14074</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14074</ArticleId><ArticleId IdType="pubmed">29057467</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo EH, Choi ES, Cho SH, Do JH, Lee SJ, Kim JH (2018) Comparison of fatigue severity and quality of life between unexplained fatigue patients and explained fatigue patients. Korean J Fam Med 39(3):180&#x2013;184. https://doi.org/10.4082/kjfm.2018.39.3.180</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.2018.39.3.180</ArticleId><ArticleId IdType="pubmed">29788707</ArticleId><ArticleId IdType="pmc">5975989</ArticleId></ArticleIdList></Reference><Reference><Citation>Daumas L, Corbel C, Zory R et al (2022) Associations, overlaps and dissociations between apathy and fatigue. Sci Rep 12(1):7387. https://doi.org/10.1038/s41598-022-11071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11071-5</ArticleId><ArticleId IdType="pubmed">35513461</ArticleId><ArticleId IdType="pmc">9072543</ArticleId></ArticleIdList></Reference><Reference><Citation>Slimani M, Znazen H, Bragazzi NL, Zguira MS, Tod D (2018) The effect of mental fatigue on cognitive and aerobic performance in adolescent active endurance athletes: insights from a randomized counterbalanced, cross-over trial. J Clin Med 7(12):510. https://doi.org/10.3390/jcm7120510</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm7120510</ArticleId><ArticleId IdType="pubmed">30513903</ArticleId><ArticleId IdType="pmc">6306934</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Nicola M, Pepe M, Montanari S et al (2023) Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes. Eur Neuropsychopharmacol 70:21&#x2013;28. https://doi.org/10.1016/j.euroneuro.2023.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2023.02.006</ArticleId><ArticleId IdType="pubmed">36808043</ArticleId><ArticleId IdType="pmc">9905099</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG (2016) A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord 206:140&#x2013;150. https://doi.org/10.1016/j.jad.2016.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.07.015</ArticleId><ArticleId IdType="pubmed">27474960</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight MJ, Baune BT (2018) Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry 31(1):33&#x2013;31. https://doi.org/10.1097/YCO.0000000000000378</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000378</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS, Wilkosz PA (2005) Disorders of diminished motivation. J Head Trauma Rehabil 20(4):377</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001199-200507000-00009</ArticleId><ArticleId IdType="pubmed">16030444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi C, Sarti R, Levi R et al (2023) Association between duration of SARS-CoV-2 positivity and long COVID. Clin Infect Dis 77(11):1531&#x2013;1533. https://doi.org/10.1093/cid/ciad434</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad434</ArticleId><ArticleId IdType="pubmed">37480344</ArticleId><ArticleId IdType="pmc">10686944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T et al (2021) Attributes and predictors of long COVID. Nat Med 27(4):633&#x2013;631. https://doi.org/10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerlind E, Palstam A, Sunnerhagen KS, Persson HC (2021) Patterns and predictors of sick leave after Covid-19 and long Covid in a national Swedish cohort. BMC Public Health 21(1):1023. https://doi.org/10.1186/s12889-021-11013-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11013-2</ArticleId><ArticleId IdType="pubmed">34059034</ArticleId><ArticleId IdType="pmc">8164957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyer N, Petruski-Ivleva N, Albert L et al (2021) Identification of a vulnerable group for post-acute sequelae of SARS-CoV-2 (PASC): people with autoimmune diseases recover more slowly from COVID-19. Int J Gen Med 14:3941&#x2013;3949. https://doi.org/10.2147/IJGM.S313486</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S313486</ArticleId><ArticleId IdType="pubmed">34345182</ArticleId><ArticleId IdType="pmc">8323859</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminian A, Bena J, Pantalone KM, Burguera B (2021) Association of obesity with postacute sequelae of COVID-19. Diabetes Obes Metab 23(9):2183&#x2013;2188. https://doi.org/10.1111/dom.14454</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14454</ArticleId><ArticleId IdType="pubmed">34060194</ArticleId><ArticleId IdType="pmc">8239834</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrea L, Grant WB, Frias-Toral E et al (2022) Dietary recommendations for post-COVID-19 syndrome. Nutrients 14(6):1305. https://doi.org/10.3390/nu14061305</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14061305</ArticleId><ArticleId IdType="pubmed">35334962</ArticleId><ArticleId IdType="pmc">8954128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno-Almaz&#xe1;n A, Pallar&#xe9;s JG, Buend&#xed;a-Romero &#xc1; et al (2021) Post-COVID-19 syndrome and the potential benefits of exercise. Int J Environ Res Public Health 18(10):5329. https://doi.org/10.3390/ijerph18105329</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18105329</ArticleId><ArticleId IdType="pubmed">34067776</ArticleId><ArticleId IdType="pmc">8156194</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu T, McGill SC (2021) An overview of post&#x2013;COVID-19 condition (long COVID). Can J Health Technol 1(9). https://doi.org/10.51731/cjht.2021.160</Citation></Reference><Reference><Citation>Huang L, Yao Q, Gu X et al (2021) 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet Lond Engl 398(10302):747&#x2013;758. https://doi.org/10.1016/S0140-6736(21)01755-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>